newsfilter
← Latest News
Business Wire·

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics,